Docket Number (Optional) **RENEWED PETITION UNDER 37 CFR 1.137(b)** 10546-109 First Named inventor: Michael J. Borrelli, Ph.D. Art Unit: 1635 Application Number: 10/764,316 Examiner: Chong, Kimberly Filed: January 23, 2004 Title: METHODS AND COMPOSITIONS FOR HEAT ACTIVATED GENE THERAPY USING CYTOLETHAL DISTENDING TOXIN Attention: Office of Petitions Mail Stop Petition Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 FAX (571) 273-8300 NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282. The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained. APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION. NOTE: A grantable petition requires the following items: (1) Petition fee. (2) Reply and/or issue fee. (3) Terminal disclaimer with disclaimer fee-required for all utility and plant applications filed before June 8, 1995, and for all design applications; and (4) Statement that the entire delay was unintentional. 1. Petition fee: Small entity-fee \$770.00 (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27. Other than small entity – fee \$____ (37 CFR 1.17(I)). 2. Reply and/or fee: A. The reply and/or fee to the above-noted Office action in the form of Amendment After Final (identify the type of reply) has been filed previously filed on _____. is enclosed herewith. B. The issue fee of \$___ has been filed previously filed on _____. is enclosed herewith.

RENEWED PETITION UNDER 37 CFR 1.137(b)		
3. Terminal disclaimer with disclai	mer fee	
☑ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.		
☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).		
STATEMENT: The entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]		
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.		
Eric J. Baude/		<u>August 25, 2008</u>
Signature		Date
Eric J. Baude Fyped or Printed Name	:	47,413 Registration No., if applicable
Brinks Hofer Gilson & Lione Address P.O. Box 10395 Address		(734) 302 6010 Telephone Number
Chicago, IL 60610		
Address		
Attachment(s) 🛛 Reply		
☐ Terminal Disclaimer Form		
Additional sheets containing statements establishing unavoidable delay		
Other: RCE; AMENDMENT AFTER FINAL (5 page).		
CERTIFICATE OF EES EII INC. LINDER 27 OFR \$4.0		
CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8 hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:		
Date: <u>August 25, 2008</u>	Name: <u>Eric J. Baude</u> Signa	ature:/EJB/